1Cademy - Vaccine Dosages in the Phase 2 Trial of the Ad5 Vector-based COVID-19 Vaccine

Concept

Vaccine Dosages in the Phase 2 Trial of the Ad5 Vector-based COVID-19 Vaccine

The vaccine dosages were chosen based on the results from the phase 1 trial
In phase 1, most of the adverse reactions were within the group that was administered 1.5X10^11 viral particles, so Zhu and colleagues decided to test 1.0X10^11 and 5.0X10^10 viral particles
It was expected that 1.0X10^11 viral particles would be the better dosage of the two doses tested because an increased antigen dose is usually associated with better immunogenicity. However, that was not the case.
It was found that 5.0x10^10 is the better of the two doses-less adverse effects and comparable immunogenicity

Updated 2020-10-09

Contributors are:

Who are from:

References